Topically applied manganese-porphyrins BMX-001 and BMX-010 display a significant anti-inflammatory response in a mouse model of allergic dermatitis

Arch Dermatol Res. 2016 Dec;308(10):711-721. doi: 10.1007/s00403-016-1693-0. Epub 2016 Oct 5.


In this study, we topically administered two antioxidant compounds, the manganese-porphyrin-derivatives BMX-001 and BMX-010, in a mouse model of allergic dermatitis and compared the efficacy for reduction of itch and inflammation. In vitro effects of BMX-001 and BMX-010 on keratinocytes, bone marrow derived dendritic cells (BMDCs) and T-cells were initially analysed. For assessment of scratching behaviour, BMX-001 and BMX-010 (0.01 and 0.1 %) were topically applied 16 h and/or 1 h before compound 48/80 or toluene-2,4,-diisocyanate (TDI) challenge in a TDI induced mouse dermatitis model. Additionally, assessment of allergic skin inflammation was performed in a similar manner in the TDI model. Post-treatment ear thickness was measured 24 h after TDI challenge and compared to basal values. The mice were sacrificed and the ear auricle was removed for further analysis. In vitro, both BMX substances significantly inhibited cytokine production of keratinocytes as well as of BMDC and T-cell proliferation. Topical treatment with BMX cream resulted in a significant decrease in scratching behaviour in the compound 48/80 model, but not in the TDI model. Mice treated with BMX-001 and BMX-010 showed a moderate dose dependent decrease in ear thickness, and interestingly, the concentration of the cytokines IL-1β and IL-4 in inflamed skin was reduced by 80-90 % by all treatment options. These first results suggest the potential benefit of a BMX-001 and BMX-010 cream for the treatment of allergic-inflammatory skin diseases.

Keywords: Allergic dermatitis; BMX-001; BMX-010; Mice; Superoxide dismutase mimics.

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Animals
  • Cell Line
  • Dendritic Cells / drug effects
  • Dendritic Cells / metabolism
  • Dermatitis, Allergic Contact / drug therapy*
  • Disease Models, Animal
  • Ear
  • Female
  • Humans
  • Infant, Newborn
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Interleukin-1beta / metabolism
  • Interleukin-4 / metabolism
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Metalloporphyrins / administration & dosage
  • Metalloporphyrins / therapeutic use*
  • Mice
  • Mice, Inbred BALB C
  • Pruritus / drug therapy*
  • Skin / drug effects*
  • Skin / metabolism
  • Skin Cream
  • Superoxide Dismutase / metabolism
  • Toluene 2,4-Diisocyanate / toxicity
  • p-Methoxy-N-methylphenethylamine / toxicity


  • IL1B protein, mouse
  • Interleukin-1beta
  • Metalloporphyrins
  • Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin
  • manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin
  • Toluene 2,4-Diisocyanate
  • Interleukin-4
  • p-Methoxy-N-methylphenethylamine
  • Superoxide Dismutase